Regeneron Pharmaceuticals (REGN) Posts Q4 Loss of 37c/Share
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q4 EPS of ($0.37), $0.23 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $123 million versus the consensus estimate of $131.04 million.
For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- UPDATE: Youku.com (YOKU) Misses Q1 EPS by 1c; Sees Q2 Sales Up 90-100% YoY
- UPDATE: Nomura Securities Upgrades ASML Inc. (ASML) to Buy; Revenue Outlook Underestimated
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
